NeuroSense sets Nov. 10 Nasdaq panel hearing after delisting notice over market value rule
NeuroSense won a Nasdaq hearing on Nov. 10, 2026, challenging an Oct. 1 staff delisting determination. Trading in NRSN and NRSNW continues pending a panel ruling; the $1.00 minimum bid-price rule is back in compliance. Remaining breach targets Nasdaq’s $35 million market-value-of-listed-securities rule; the company wil